纽尔真检测 NEOG 深 沪
交易中 09-16 11:00:46 美东时间
12.77
+0.520
+4.24%
华盛通- 最 高12.79
- 今 开12.30
- 成交量 33.06万股
- 最 低 12.30
- 昨 收 12.25
- 总市值 27.85亿
- 52周最高 12.85
- 市盈率 静 --
- 换手率 0.15%
- 52周最低 5.37
- 委 比 12.94%
- 总股本 2.18亿
- 历史最高 48.85
- 量 比 0.57
- 振 幅 4.00%
- 历史最低 3.8701
- 每 手 1
- 风险率 1.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neogen Chemicals Restructures Subsidiary Assets in Rs 245-Crore Transfer
Neogen Chemicals Ltd. ( ($IN:NEOGEN) ) has provided an announcement. Neogen Che...
09-01 03:34
美股大行评级 | 潜在涨幅1849.95%！Ascendiant Capital上调IGC Pharma目标价至6美元，维持"买入"评级；迪克体育、财捷遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.5美元升至6美元；Ascendiant Capital：维持Quantum Computing"买入"评级，目标价从30美元升至32美元
08-27 08:37
Piper Sandler Upgrades Neogen to Overweight, Raises Price Target to $14
Piper Sandler analyst David Westenberg upgrades Neogen (NASDAQ:NEOG) from Neutral to Overweight and raises the price target from $13 to $14.
08-27 00:45
Neogen upgraded at Piper Sandler on new management
Piper Sandler on Wednesday upgraded Neogen Corporation (NEOG) to Overweight from Neutral and raised its price target to $14 from $13 per share, arguing that the food safety company is turning a corner...
08-26 23:00
Sera Prognostics appoints Scott Gleason as CFO, effective Aug. 31
Sera Prognostics (SERA) announced on Wednesday that Scott Gleason will become CFO, effective August 31, 2026. Gleason has more than 25 years of healthcare, diagnostics, and capital markets experience ...
08-20 04:38
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals reported progress in its oncology and obesity pipeline, obtaining FDA clearance for the registrational study of CRB-701 in oropharyngeal cancer and completing the last patient visit in the CANYON-1 trial of CRB-913 for obesity. The company also appointed new leadership to strengthen its team. Financially, Corbus reported a net loss of $35 million for the second quarter, with $117.9 million in cash on hand.
08-06 12:00
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Piper Sandler Reiterates Neutral on Neogen, Raises Price Target to $13
Piper Sandler analyst David Westenberg reiterates Neogen (NASDAQ:NEOG) with a Neutral and raises the price target from $11 to $13.
08-04 00:02
Neogen’s Evolving Business Model Keeps Internal Controls a Key Financial Risk
Neogen (NEOG) has disclosed a new risk, in the Accounting & Financial Opera...
08-01 14:01
Neogen shares are trading higher after the company reported better-than-expected Q4 financial results.
Neogen shares are trading higher after the company reported better-than-expected Q4 financial results.
07-31 01:52
